Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Antje Danielczyk"'
Autor:
Patrik Kehler, Timo Lischke, Antje Danielczyk, Johanna Gellert, Theresa Neumann, Evelyn Hartung, Stephanie Gurka, Naomi Kast, Lisa Weiß, Luisa Willmann, Sophie Marinoff, Sven Barke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f0248c5c8a474100a458920fd4f8c689
Autor:
Theresa Neumann, Evelyn Hartung, Johanna Gellert, Lisa Weiß, Manon Weiske, Naomi Kast, Stephanie Gurka, Sophie Marinoff, Anika Jäkel, Antje Danielczyk, Patrik Kehler
Publikováno v:
Frontiers in Drug Discovery, Vol 3 (2023)
Introduction: One of the most drastic changes in cancer is the altered glycosylation of proteins and lipids, giving rise to truncated O-glycans like the Thomsen Friedenreich (TF) or Thomsen nouvelle (Tn) antigen, which are almost absent on normal cel
Externí odkaz:
https://doaj.org/article/1642fa48651b41748ba0b68dfa45fd4f
Autor:
Anika Jaekel, Patrik Kehler, Timo Lischke, Christoph Goletz, Anke Flechner, Antje Danielczyk, Johanna Gellert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6dfe5e8da513473db627f741b64f95a0
Autor:
Christoph Goletz, Timo Lischke, Ulf Harnack, Phillip Schiele, Antje Danielczyk, Johanna Rühmann, Steffen Goletz
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis plays a central role in suppression of anti-tumor immunity. Blocking the axis by targeting PD-L1 with monoclonal antibodies is an effective and already clinically approved approach
Externí odkaz:
https://doaj.org/article/a53aaa74cb764b759ae7da62e1accd4c
Publikováno v:
Bioengineering, Vol 4, Iss 2, p 42 (2017)
IgA antibodies have great potential to improve the functional diversity of current IgG antibody-based cancer immunotherapy options. However, IgA production and purification is not well established, which can at least in part be attributed to the more
Externí odkaz:
https://doaj.org/article/18c09a9858e24b12b646ce90f8009e58
Autor:
Mascha Binder, Carsten Bokemeyer, Sonja Loges, Boris Fehse, Kristoffer Riecken, Rainald Knecht, Martin Trepel, Bruno Märkl, Elzbieta Jakubowicz, Steffen Goletz, Antje Danielczyk, Simon Laban, Ingke Braren, Isabel Ben Batalla, Anja Thalhammer, Markus Sack, Veronique Blanchard, Karina Biskup, Tobias Grob, Beate Habel, Minna Voigtlaender, Malte Kriegs, Friederike Braig
Supplementary Figure 1. Inhibitory effect of Cetuximab determined by western blot analysis of 12 HNSCC cell line lysates. Supplementary Figure 2. Time course of EGFR phosphorylation in HNSCC cell line UT-SCC 8. Supplementary Figure 3. Correlation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f2861dab98115ba59a2863d22258b88
https://doi.org/10.1158/0008-5472.22416219.v1
https://doi.org/10.1158/0008-5472.22416219.v1
Autor:
Mascha Binder, Carsten Bokemeyer, Sonja Loges, Boris Fehse, Kristoffer Riecken, Rainald Knecht, Martin Trepel, Bruno Märkl, Elzbieta Jakubowicz, Steffen Goletz, Antje Danielczyk, Simon Laban, Ingke Braren, Isabel Ben Batalla, Anja Thalhammer, Markus Sack, Veronique Blanchard, Karina Biskup, Tobias Grob, Beate Habel, Minna Voigtlaender, Malte Kriegs, Friederike Braig
Supplementary Table 1 Patient characteristics including EGFRK521 allele frequency. Supplementary Table 2 Characteristics and sequencing data of squamous cell carcinoma cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bf07edc18e7ba91ca942179f80df7e1
https://doi.org/10.1158/0008-5472.22416216
https://doi.org/10.1158/0008-5472.22416216
Autor:
Mascha Binder, Carsten Bokemeyer, Sonja Loges, Boris Fehse, Kristoffer Riecken, Rainald Knecht, Martin Trepel, Bruno Märkl, Elzbieta Jakubowicz, Steffen Goletz, Antje Danielczyk, Simon Laban, Ingke Braren, Isabel Ben Batalla, Anja Thalhammer, Markus Sack, Veronique Blanchard, Karina Biskup, Tobias Grob, Beate Habel, Minna Voigtlaender, Malte Kriegs, Friederike Braig
Supplemental Figures 1 to 6 from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b4bc16eeae53fa30a4b111b627183ce
https://doi.org/10.1158/0008-5472.22416222
https://doi.org/10.1158/0008-5472.22416222
Autor:
Mascha Binder, Carsten Bokemeyer, Sonja Loges, Boris Fehse, Kristoffer Riecken, Rainald Knecht, Martin Trepel, Bruno Märkl, Elzbieta Jakubowicz, Steffen Goletz, Antje Danielczyk, Simon Laban, Ingke Braren, Isabel Ben Batalla, Anja Thalhammer, Markus Sack, Veronique Blanchard, Karina Biskup, Tobias Grob, Beate Habel, Minna Voigtlaender, Malte Kriegs, Friederike Braig
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-targeting drug cetuximab poses a challenge to their effective clinical management. Here, we report a specific mechanism of resistance in this setting based upon the pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b25965099290cbcc9845191154ace7fe
https://doi.org/10.1158/0008-5472.c.6509496.v1
https://doi.org/10.1158/0008-5472.c.6509496.v1
Autor:
Patrik Kehler, Theresa Neumann, Anika Jaekel, Johanna Gellert, Antje Danielczyk, Lisa Weiß, Luisa Willmann, Stephanie Gurka, Naomi Kast, Manon Weiske
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0feef532eb2b18842364c904cfe099d0
https://doi.org/10.1136/jitc-2022-sitc2022.1347
https://doi.org/10.1136/jitc-2022-sitc2022.1347